Literature DB >> 22654471

Predictors of provisional stenting in patients undergoing lower extremity arterial interventions.

Nicolas W Shammas1, Denise Coiner, Gail Shammas, Michael Jerin.   

Abstract

Predictors of provisional stenting in patients undergoing lower extremity arterial interventions remain unclear. We performed an ad hoc analysis on the predictors of provisional stenting during infrainguinal arterial percutaneous interventions using data from the Percutaneous Lower Extremity Arterial Interventions Using Primary Balloon Angioplasty versus Silverhawk Atherectomy (SA) and Adjunctive Balloon Angioplasty trial. In the above trial, SA of infrainguinal de novo arterial lesions was shown to reduce significantly provisional stenting compared with primary percutaneous transluminal angioplasty (PTA). In this ad hoc analysis, patients were divided into two groups based on whether provisional stenting has occurred. Univariate analysis was conducted between the stent versus the no-stent group. Logistic regression (LR) analysis was performed to model for the predictors of provisional stenting. Variables included were diabetes, presence of moderate calcification (versus none to little), age, gender, hypercholesterolemia, Transatlantic Intersociety Consensus (TASC) D lesion (vs. TASC A to C), and treatment method (primary PTA vs. SA with adjunctive PTA). By LR analysis, predictors of stenting were as follows: moderate calcification (odds ratio [OR] 6.56, 95% confidence interval [CI] 1.21 to 35.56, p = 0.029), primary PTA (vs. SA) (OR 0.19, 95% CI 0.04 to 0.93, p = 0.04), and TASC D lesions (vs. A to C) (OR 0.10, 95% CI 0.01 to 0.87, p = 0.037). Provisional stenting in infrainguinal interventions is predicted by the use of primary PTA, presence of moderate calcification, and TASC D lesions after controlling for gender, age, hypercholesterolemia, and diabetes.

Entities:  

Keywords:  Peripheral angioplasty; atherectomy; long occlusions; predictors of stenting; vessel calcification

Year:  2011        PMID: 22654471      PMCID: PMC3331633          DOI: 10.1055/s-0031-1279683

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  11 in total

1.  Peripheral arterial balloon angioplasty: effect of short versus long balloon inflation times on the morphologic results.

Authors:  Niels Zorger; Christoph Manke; Markus Lenhart; Thomas Finkenzeller; Behrus Djavidani; Stefan Feuerbach; Johann Link
Journal:  J Vasc Interv Radiol       Date:  2002-04       Impact factor: 3.464

2.  Long-term results after directional atherectomy of femoro-popliteal lesions.

Authors:  Thomas Zeller; Aljoscha Rastan; Sebastian Sixt; Uwe Schwarzwälder; Thomas Schwarz; Ulrich Frank; Karlheinz Bürgelin; Christian Müller; Uwe Rothenpieler; Peter-Christian Flügel; Gunnar Tepe; Franz-Josef Neumann
Journal:  J Am Coll Cardiol       Date:  2006-09-26       Impact factor: 24.094

3.  Routine stent implantation vs. percutaneous transluminal angioplasty in femoropopliteal artery disease: a meta-analysis of randomized controlled trials.

Authors:  Christos Kasapis; Peter K Henke; Stanley J Chetcuti; Gerald C Koenig; John E Rectenwald; Venkataramu N Krishnamurthy; Paul Michael Grossman; Hitinder S Gurm
Journal:  Eur Heart J       Date:  2008-11-21       Impact factor: 29.983

4.  Long-segment SFA stenting--the dark sides: in-stent restenosis, clinical deterioration, and stent fractures.

Authors:  Oliver Schlager; Petra Dick; Schila Sabeti; Jasmin Amighi; Wolfgang Mlekusch; Erich Minar; Martin Schillinger
Journal:  J Endovasc Ther       Date:  2005-12       Impact factor: 3.487

5.  Midterm outcomes from the TALON Registry: treating peripherals with SilverHawk: outcomes collection.

Authors:  Venkatesh Ramaiah; Roger Gammon; Stefan Kiesz; Joseph Cardenas; John Paul Runyon; Peter Fail; Craig Walker; David E Allie; Jack Chamberlin; Maurice Solis; Lawrence Garcia; David Kandzari
Journal:  J Endovasc Ther       Date:  2006-10       Impact factor: 3.487

6.  Prevalence and clinical impact of stent fractures after femoropopliteal stenting.

Authors:  Dierk Scheinert; Susanne Scheinert; Jacqueline Sax; Christopher Piorkowski; Sven Bräunlich; Matthias Ulrich; Giancarlo Biamino; Andrej Schmidt
Journal:  J Am Coll Cardiol       Date:  2005-01-18       Impact factor: 24.094

7.  Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery.

Authors:  Martin Schillinger; Schila Sabeti; Christian Loewe; Petra Dick; Jasmin Amighi; Wolfgang Mlekusch; Oliver Schlager; Manfred Cejna; Johannes Lammer; Erich Minar
Journal:  N Engl J Med       Date:  2006-05-04       Impact factor: 91.245

8.  Infrainguinal atherectomy: a retrospective review of a single-center experience.

Authors:  Nataliya I Biskup; Daniel M Ihnat; Luis R Leon; Angelika C Gruessner; Joseph L Mills
Journal:  Ann Vasc Surg       Date:  2008-11       Impact factor: 1.466

9.  Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST).

Authors:  Hans Krankenberg; Michael Schlüter; Hermann J Steinkamp; Karlheinz Bürgelin; Dierk Scheinert; Karl-Ludwig Schulte; Erich Minar; Patrick Peeters; Marc Bosiers; Gunnar Tepe; Bernhard Reimers; Felix Mahler; Thilo Tübler; Thomas Zeller
Journal:  Circulation       Date:  2007-06-25       Impact factor: 29.690

Review 10.  Limitations of percutaneous transluminal angioplasty and stenting for the treatment of disease of the superficial femoral and popliteal arteries.

Authors:  John R Laird
Journal:  J Endovasc Ther       Date:  2006-02       Impact factor: 3.487

View more
  9 in total

Review 1.  JETSTREAM Atherectomy: A Review of Technique, Tips, and Tricks in Treating the Femoropopliteal Lesions.

Authors:  Nicolas W Shammas
Journal:  Int J Angiol       Date:  2015-06

Review 2.  An overview of optimal endovascular strategy in treating the femoropopliteal artery: mechanical, biological, and procedural factors.

Authors:  Nicolas W Shammas
Journal:  Int J Angiol       Date:  2013-03

Review 3.  Emerging stent and balloon technologies in the femoropopliteal arteries.

Authors:  Georgios Pastromas; Konstantinos Katsanos; Miltiadis Krokidis; Dimitrios Karnabatidis; Stavros Spiliopoulos
Journal:  ScientificWorldJournal       Date:  2014-02-04

4.  Effective endovascular treatment of calcified femoropopliteal disease with directional atherectomy and distal embolic protection: final results of the DEFINITIVE Ca⁺⁺ trial.

Authors:  David Roberts; Khusrow Niazi; William Miller; Prakash Krishnan; Roger Gammon; Theodore Schreiber; Nicolas W Shammas; Daniel Clair
Journal:  Catheter Cardiovasc Interv       Date:  2014-02-05       Impact factor: 2.692

5.  Use of the directional atherectomy for the treatment of femoro-popliteal lesions in patients with critical lower limb ischemia.

Authors:  Umberto Marcello Bracale; Gaetano Vitale; Guido Bajardi; Donatella Narese; Ettore Dinoto; Anna Maria Giribono; Doriana Ferrara; Luca Del Guercio; Massimo Midiri; Felice Pecoraro
Journal:  Transl Med UniSa       Date:  2016-11-01

6.  Platelet to lymphocyte ratio predicting 6-month primary patency of drug-coated balloon for femoropopliteal disease.

Authors:  Yanhua Zhen; Zhihui Chang; Zhaoyu Liu; Jiahe Zheng
Journal:  BMC Cardiovasc Disord       Date:  2020-01-09       Impact factor: 2.298

7.  Jetstream Atherectomy Followed by Paclitaxel-Coated Balloons versus Balloon Angioplasty Followed by Paclitaxel-Coated Balloons: Twelve-Month Exploratory Results of the Prospective Randomized JET-RANGER Study.

Authors:  Nicolas W Shammas; Bhaskar Purushottam; W John Shammas; Lori Christensen; Gail Shammas; Desyree Weakley; Sue Jones-Miller
Journal:  Vasc Health Risk Manag       Date:  2022-08-02

8.  Atherectomy for peripheral arterial disease.

Authors:  Bethany G Wardle; Graeme K Ambler; Rami W Radwan; Robert J Hinchliffe; Christopher P Twine
Journal:  Cochrane Database Syst Rev       Date:  2020-09-29

Review 9.  Current developments in endovascular therapy of peripheral vascular disease.

Authors:  Damianos G Kokkinidis; Ehrin J Armstrong
Journal:  J Thorac Dis       Date:  2020-04       Impact factor: 3.005

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.